AbbVie and Allergan announced Tuesday, March 17, that they signed a consent decree with the US Federal Trade Commission that will commit the companies to selling some properties if they commence a planned merger.
As previously announced, the companies plan to sell brazikumab, an experimental Crohn’s disease and ulcerative colitis treatment, to AstraZeneca and pancreatic treatment Zenpep to Nestlé.
Tuesday’s announcement also stated that Nestlé plans to purchase Viokace, a similar product. The companies stated they expect the deal to close in May.
Full Content: Market Watch
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
